BioTuesdays

Tag - MLTX

MoonLake Logo
Markets

BTIG starts Moonlake at buy; PT $36

BTIG initiated coverage of Moonlake Immunotherapeutics (NASDAQ:MLTX) with a “buy” rating and $36 price target. The stock closed at $23.70 on March 8. “We see Moonlake’s sonelokimab (SLK) well-positioned to emerge as the...

March 9, 2023
MoonLake Logo
Markets

Cantor starts MoonLake at OW; PT $23

Cantor Fitzgerald initiated coverage of MoonLake Immunotherapeutics (NASDAQ:MLTX) with an “overweight” rating and a 12-month price target of $23. The stock closed at $16.30 on Feb. 13. MoonLake has an IL-17A and IL-17F...

February 14, 2023
MoonLake Logo
Markets

SVB starts Moonlake at OP; PT $17

SVB Securities launched coverage of Moonlake Immunotherapeutics (NASDA:MLTX) with an “outperform” rating and $17 price target. The stock closed at $9.01 on Aug. 24. Moonlake is a clinical-stage biopharmaceutical company...

August 25, 2022